Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03050463 · ClinicalTrials.gov registry record
Functional Magnetic Resonance Imaging in Assessing Affect Reactivity and Regulation in Patients With Stage 0-III Breast Cancer
A clinical trial of Stage IIIA Breast Cancer and Stage IIIB Breast Cancer, sponsored by Stanford University.
- Completed
- Registry status
- 178
- Enrollment target
- 1
- Study location
NCT03050463 is a study of Stage IIIA Breast Cancer and Stage IIIB Breast Cancer that has completed, run by Stanford University. The registered enrollment target is 178 participants, below the 275-participant average among 29 other Stage IIIA Breast Cancer trials with a reported enrollment target (35% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03050463, a study of Stage IIIA Breast Cancer and Stage IIIB Breast Cancer, has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- 178 participants
- Enrollment target
- 1
- Study location
Study Summary
The investigators hope to gain a better understanding of the influence of affect reactivity and regulation on the decision of newly diagnosed breast cancer patients to choose bilateral mastectomy. The information gained can help develop an intervention to enable management of cancer-related anxiety by non-surgical means.
Conditions Studied
Interventions
- PROCEDURE Biospecimen Collection
- OTHER Questionnaire Administration
- PROCEDURE Functional Magnetic Resonance Imaging
Study Locations (1)
California
- Stanford University, School of Medicine - Palo Alto
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 178 participants |
| Start Date | 2016-08 |
| Est. Completion | 2021-07-08 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03050463
The ClinicalTrials.gov registry entry for NCT03050463 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 178 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 275-participant average among 29 other Stage IIIA Breast Cancer trials with a reported enrollment target (35% lower). The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 9 conditions, with Stage IIIA Breast Cancer appearing as the primary indexed condition, and to 3 interventions - of which Biospecimen Collection is the first listed.
NCT03050463 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT03050463 about?
NCT03050463 is a clinical study titled "Functional Magnetic Resonance Imaging in Assessing Affect Reactivity and Regulation in Patients With Stage 0-III Breast Cancer". The investigators hope to gain a better understanding of the influence of affect reactivity and regulation on the decision of newly diagnosed breast cancer patients to choose bilateral mastectomy. The information gained can help develop an intervention to enable management of cancer-related anxiety ...
What is the current status of trial NCT03050463?
This trial is currently completed. The enrollment target is 178 participants. The study started on 2016-08. Estimated completion is 2021-07-08.
What conditions does trial NCT03050463 study?
This clinical trial studies the following conditions: Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IIA Breast Cancer, Healthy Subject.
What interventions are being tested in trial NCT03050463?
The interventions under investigation include: Biospecimen Collection (PROCEDURE), Questionnaire Administration (OTHER), Functional Magnetic Resonance Imaging (PROCEDURE).
Who is sponsoring clinical trial NCT03050463?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03050463 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Stage IIIA Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer
RECRUITING · Phase 2
-
Pegylated Liposomal Doxorubicin Hydrochloride and Carboplatin Followed by Surgery and Paclitaxel in Treating Patients With Triple Negative Stage II-III Breast Cancer
ACTIVE NOT RECRUITING · Phase 2
-
Pertuzumab, Trastuzumab, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With HER2-Positive Advanced Breast Cancer
ACTIVE NOT RECRUITING · Phase 2
-
Platinum in Treating Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy
ACTIVE NOT RECRUITING · Phase 3
-
Carboplatin and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Locally Advanced or Inflammatory Triple Negative Breast Cancer
ACTIVE NOT RECRUITING · Phase 2
-
A Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms (AIMSS)
ACTIVE NOT RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.